INTRODUCTION
A ge-relatedmaculardegeneration(AMD)istheleading causeofvisionlossamongolderadults(aged>65y)in populations,andthewet(neovascularorexudative)formof AMDproducesseverevisualloss.Asithasbeenestimated that25%ofAsianswillbe>60yearsoldby2050 [1] ,AMD willlikelybecomeamajorpublichealthproblemproducing asignificanteconomicburden.Whilethepathogenesisof AMDisnotentirelyclear,itappearstoinvolvethecomplex modulationofseveralmolecularfactors,includingvascular endothelialgrowthfactor(VEGF)andpigment epithelium-derivedfactor(PEDF).VEGFisasignalling proteinthatstimulatesvasculogenesisandangiogenesis,and playsakeyroleintheneovascularizationprocesswhich occursinAMD [2] .PEDFisbelievedtobethemostpotent naturalinhibitorofangiogenesisintheretinaandchoroidof theeye [3] [4] .Intravitrealinjectionsofanti-VEGFagentsare currentlyconsideredanintegralpartofthestandardtreatment regimenforneovascularAMD [5] ;however,thisapproachhas somedisadvantages.Thecurrentresearchondeliveryofthe geneusingtraditionaltechniqueshasbeenlimitedto experimentalstudies.Noclinicalstudieshavebeen conductedbecauseoftheshortdurationofgeneexpression achieved,thedifficultyinmaintainingthegeneinits activatedstate [6] [7] [8] , [12] [13] .Ithas beensuggestedthatanimbalancedexpressionofstimulators andinhibitorsofbloodvesselgrowthsignificantlycontributes to thepathogenesisof neovascularization,andseveral therapeuticagentshavedemonstratedanabilitytodecrease theamountofneovascularization [13] .VEGFiscurrently believedtobethemosteffectivefactorforpromotingvessel growth,whereasPEDFisbelievedtobethemostpotent naturalinhibitorofretinalandchoroidalangiogenesis [4] .The roleofVEGFinCNVdevelopmenthasbeenintensively investigated.Forexample,VEGFproductionisupregulated duringinbothhumanCNVandlaser-inducedCNV. Furthermore,administrationofexogenousVEGFpromotes CNV,whileinhibitionofVEGFactivityleadstoCNV suppression.TworeceptorsforVEGFhavebeenidentified, andarereferredtoasVEGFR-1andVEGFR-2,respectively. VEGFR-2isalsoreferredtoasFlk-1,andplaysapivotalrole inCNV.VEGFR-2isexpressedinallendothelialcellsand canbedetectedonretinalprogenitorcells.Incontrasttothe controversialroleofVEGFR-1intheneovascularization process,the VEGFR-2-mediatedsignalingpathwayis generallyconsideredtopromotetheformationofnewblood vessels [14] [15] .Intravitrealinjectionsofanti-VEGFagentsare currentlyapartofthestandardtreatmentregimenfor neovascularAMD [5] .However,suchagentshavesome disadvantages,suchasashorthalf-time,whichleadstothe needforrepeatedinjections.Atherapeuticstrategythat combinesananti-VEGFagentwithasecondtherapeutic modalitythathasadifferentmechanismofactionwould representanimportantstepforwardinthetreatmentofAMD. Asthemosteffectiveantiangiogenicfactor,PEDFhasbeen thefocusofcurrentresearchonwaystoinhibitangiogenesis. EndogenouscellularPEDFwasfirstidentifiedinthe conditionedmediaofculturedhumanfetalRPEcellsby Tombran-TinkandJohnsonin1989 [16] .PEDFisa50kDa
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